No Known Benefits Found
No clinical data or studies document benefits of using lurbinectedin (Zepzelca) while breastfeeding. Lurbinectedin is a chemotherapy agent approved for metastatic small cell lung cancer, and its use during lactation focuses on safety risks rather than advantages.[1]
Breastfeeding Safety Concerns with Lurbinectedin
Lurbinectedin is excreted into breast milk in animal models, and human data suggest it could harm nursing infants due to its cytotoxic effects on rapidly dividing cells. Major resources recommend avoiding breastfeeding during treatment and for at least 21 days after the last dose to prevent infant exposure.[2][3] No benefits outweigh these risks in available evidence.
Why No Benefits Are Documented
Lurbinectedin's mechanism—inhibiting DNA repair in cancer cells—offers no therapeutic role for breastfeeding mothers or infants. Research prioritizes oncology trials in non-lactating patients, with no trials exploring lactation-specific uses. Post-marketing data also lacks reports of breastfeeding benefits.[1]
Alternatives During Breastfeeding
For cancer treatment while breastfeeding, options like hormone therapies (e.g., tamoxifen in select cases) or non-systemic treatments may be considered, but decisions require oncologist input. Pump-and-dump strategies do not apply here due to prolonged drug clearance.[2] Consult LactMed or a specialist for personalized risks.
Regulatory and Manufacturer Guidance
The Zepzelca label advises against breastfeeding due to potential toxicity, with no mention of benefits.[1] FDA pregnancy/lactation categories highlight genotoxicity risks, aligning with EMA guidance.[4]
Sources
[1]: Zepzelca Prescribing Information (FDA)
[2]: LactMed: Lurbinectedin
[3]: Drugs.com: Lurbinectedin and Breastfeeding
[4]: EMA Product Information